Drug delivery and therapeutic impact of extended-release acetylsalicylic acid

Kevin P. Bliden, Jeff Patrick, Andrew T. Pennell, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalReview article

Abstract

Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalFuture Cardiology
Volume12
Issue number1
DOIs
StatePublished - Jan 2016

Keywords

  • Durlaza
  • acetylsalicylic acid
  • antiplatelet
  • cardiovascular disease
  • diabetes
  • extended-release
  • microcapsule
  • secondary prevention
  • thrombosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Drug delivery and therapeutic impact of extended-release acetylsalicylic acid'. Together they form a unique fingerprint.

  • Cite this

    Bliden, K. P., Patrick, J., Pennell, A. T., Tantry, U. S., & Gurbel, P. A. (2016). Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. Future Cardiology, 12(1), 45-58. https://doi.org/10.2217/fca.15.60